Developer docs
API playgroundTry for free, no card

Search company profiles

Centile Bioscience

Full company profile

uuid00sdnsb

Namestring
Centile Bioscience
Legal namestring
Centile Bio
Websiteurl
centilebio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Centile Bioscience (operating as Centile Bio) is a private, Delaware-incorporated health technology company founded in January 2023 that builds quantitative brain imaging and computational neuroscience infrastructure. Its core products are population-scale Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure for reproducible analysis, and an Advanced Statistical Modeling Platform for neuroimaging datasets. Together these tools transform MRI and CT brain data into measurable quantitative insight rather than qualitative visual interpretation, using computer vision, deep learning–based brain tissue classification, predictive analytics, and harmonization of heterogeneous multi-institution datasets. The company is research-validated through publications in Nature, Radiology, JAMA Psychiatry and other high-impact journals, and through the NIH/FASEB DataWorks! Challenge Grand Prize (2023).

The company serves two defined customer segments: primary customers are research institutions and academic medical centers conducting neuroscience research and neuroimaging studies, with use cases in neurological disease research, clinical trial endpoint development and therapeutic discovery; secondary customers are pharmaceutical and biotech companies that need objective biomarkers, patient stratification and clinical trial endpoint validation for neurological therapeutics. Its go-to-market is enterprise B2B — direct research collaboration and technology licensing with leading academic and clinical partners globally — rather than a self-serve product. The company is headquartered in Wilmington, Delaware (registered address) and reports team affiliations spanning Children's Hospital of Philadelphia, University of Pennsylvania, MIT, Brigham and Women's Hospital, King's College London, University of Cambridge, Harvard MGB and AIM-Harvard, with active clinical validation programs for Alzheimer's disease and Normal Pressure Hydrocephalus.

Commercial revenue is undisclosed and the company appears to be in a pre-commercial research and validation stage: the only funding identified is the NIH/FASEB prize grant in January 2023 (which also coincided with founding), headcount is reported at 1–10, and no named commercial customers, contract values, or pricing are public. Growth is being driven by grant-funded research collaborations (TBI-REPORTER, COVID-19 long COVID consortium), diagnostic validation paper submissions, and senior hires in product, engineering, and machine learning — indicating a transition from pure research toward a licensable clinical and pharma-facing platform rather than a scaled commercial product today.

Short descriptiontext

Centile Bioscience is a private health technology company founded in 2023 that builds AI-driven quantitative brain imaging and reference models for research institutions, academic medical centers, and pharmaceutical companies developing neurological therapeutics and clinical trial endpoints.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBethesda, United States
HQ citystring
Bethesda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
quantitative brain imaging, computational neuroscience, neuroimaging analytics, brain reference models, neurological diagnostics
Industry4 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Neuroimaging Analytics Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Research and Clinical Technology Licensing
TypeLicensing Royalties
Description

The company appears to generate revenue through licensing its quantitative brain imaging technology and reference frameworks to research institutions, pharmaceutical companies, and healthcare organizations for use in clinical trials, drug discovery, and neurological disease research.

centilebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Centile Bio builds advanced computational and imaging frameworks that transform complex brain data (MRI, CT) into measurable quantitative insight. Its software offerings include Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure, and an Advanced Statistical Modeling Platform for neuroimaging datasets, sold via licensing to research institutions, academic medical centers, and pharmaceutical companies for use in clinical trials, drug discovery, and neurological disease research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Earlier detection of neurological disease through quantitative biological signal identification
+1 more record
Product overview1 text field

Centile Bio offers a unified quantitative neuroscience platform comprising four integrated core products: Quantitative Brain Reference Models for population-scale brain structure measurement, a Large-Scale Neuroimaging Analysis Platform for interpreting complex imaging data, Computational Modeling Infrastructure for reproducible brain analysis, and an Advanced Statistical Modeling Platform for neuroimaging datasets. These products work together to transform complex brain imaging data into measurable quantitative insight, enabling earlier detection, deeper understanding, and accelerated therapeutic discovery in neurological disease.

Product and service4 records
1Quantitative Brain Reference Models
CategoryCore Product
Description

Population-scale statistical frameworks for measuring brain structure and variation across individuals, ages, and populations, enabling researchers to move beyond visual interpretation toward measurable, quantitative insight for neuroscience research and clinical studies.

2Large-Scale Neuroimaging Analysis Platform
CategoryCore Product
Description

Advanced statistical systems for interpreting complex brain imaging data and integrating diverse neuroimaging datasets across large cohorts, enabling consistent analysis and pattern identification for research institutions and pharmaceutical partners.

3Computational Modeling Infrastructure
4Advanced Statistical Modeling Platform for Neuroimaging
CategoryCore Product
Description

Statistical modeling platform for neuroimaging datasets launched in 2024, supporting earlier detection of neurological changes and improved analytical tools for studying neurological disorders across research and clinical workflows.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1COVID-19 Consortium for Brain Charting in Long COVID Patients
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

CentileBio formed research collaboration with COVID-19 consortium to advance brain charting research specifically focused on long COVID patients, contributing to understanding of neurological impacts of the pandemic.

centilebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global scientific collaboration with leading research institutions, clinical partners, and data initiatives advancing quantitative neuroscience discovery. Millions of brain imaging data points analyzed through these partnerships.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Centile Bio team received DataWorks! Challenge grand prize from National Institutes of Health and Federation of American Societies for Experimental Biology, recognizing contributions to quantitative neuroscience research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple team members are affiliated with CHOP including CEO Jakob Seidlitz and Scientific Advisor Aaron Alexander-Bloch. The company leverages CHOP's research infrastructure and neuroimaging capabilities.

5Scandx AB Sweden
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Michael and Meera joined as co-founders through exclusive deal with Scandx AB Sweden, bringing additional expertise and technology to Centile Bio.

centilebio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Brainreader offers AI-based brain MRI volumetrics (Neuroreader) used by clinicians and pharma trials to quantify brain changes — comparable product and customer overlap with Centile's quantitative measurement products.

TypeBroad incumbent
Description

Siemens Healthineers is a major MRI and imaging AI incumbent whose AI-Rad Companion and neurology analytics compete or partner with vendors like Centile in quantitative brain measurement.

TypeBroad incumbent
Description

Aidoc is a broad AI-imaging vendor with FDA-cleared algorithms deployed across hospital radiology workflows; competes for enterprise imaging-AI budgets that Centile would also target via its neurology-focused platform.

TypeDirect peer
Description

icometrix develops AI software (icobrain) that quantitatively analyzes brain MRI/CT scans for neurological conditions including MS, dementia and TBI — the closest direct peer to Centile's quantitative brain reference and imaging-analysis platform.

TypeDirect peer
Description

QMENTA provides a cloud-based neuroimaging analysis platform for clinical trials and research, very analogous to Centile's large-scale neuroimaging analysis infrastructure for multi-site brain studies.

TypeEmerging player
Description

Neotiv develops digital biomarkers and AI analysis for memory and early Alzheimer's detection, overlapping with Centile's AD validation work in the same neurodegenerative diagnostic category.

TypeBroad incumbent
Description

GE Healthcare is a large incumbent in MRI equipment and increasingly AI-augmented neuroimaging analytics; represents the platform/channel partner versus which Centile's AI must differentiate.

TypeEmerging player
Description

Altoida builds AI-based digital cognitive and brain-health assessment tools targeting early detection of neurodegenerative disease, addressing similar end-markets via a different (digital-cognitive) modality.

TypeDirect peer
Description

CorTechs Labs commercializes NeuroQuant, an FDA-cleared brain MRI volumetric analysis tool widely used in clinical practice; directly comparable to Centile's quantitative brain measurement and diagnostic validation roadmap.

TypeDirect peer
Description

Octave Bioscience builds AI-enabled multi-modal diagnostics for neurodegenerative diseases (notably MS); Centile's CSPO Kelly Leyden previously led product there, and the company competes for the same neurology-diagnostics B2B customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Centile Bioscience

Neuroimaging Analytics Softwarecentilebio.com

Centile Bioscience is a private health technology company founded in 2023 that builds AI-driven quantitative brain imaging and reference models for research institutions, academic medical centers, and pharmaceutical companies developing neurological therapeutics and clinical trial endpoints.

What Centile Bioscience does

Centile Bioscience (operating as Centile Bio) is a private, Delaware-incorporated health technology company founded in January 2023 that builds quantitative brain imaging and computational neuroscience infrastructure. Its core products are population-scale Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure for reproducible analysis, and an Advanced Statistical Modeling Platform for neuroimaging datasets. Together these tools transform MRI and CT brain data into measurable quantitative insight rather than qualitative visual interpretation, using computer vision, deep learning–based brain tissue classification, predictive analytics, and harmonization of heterogeneous multi-institution datasets. The company is research-validated through publications in Nature, Radiology, JAMA Psychiatry and other high-impact journals, and through the NIH/FASEB DataWorks! Challenge Grand Prize (2023).

The company serves two defined customer segments: primary customers are research institutions and academic medical centers conducting neuroscience research and neuroimaging studies, with use cases in neurological disease research, clinical trial endpoint development and therapeutic discovery; secondary customers are pharmaceutical and biotech companies that need objective biomarkers, patient stratification and clinical trial endpoint validation for neurological therapeutics. Its go-to-market is enterprise B2B — direct research collaboration and technology licensing with leading academic and clinical partners globally — rather than a self-serve product. The company is headquartered in Wilmington, Delaware (registered address) and reports team affiliations spanning Children's Hospital of Philadelphia, University of Pennsylvania, MIT, Brigham and Women's Hospital, King's College London, University of Cambridge, Harvard MGB and AIM-Harvard, with active clinical validation programs for Alzheimer's disease and Normal Pressure Hydrocephalus.

Commercial revenue is undisclosed and the company appears to be in a pre-commercial research and validation stage: the only funding identified is the NIH/FASEB prize grant in January 2023 (which also coincided with founding), headcount is reported at 1–10, and no named commercial customers, contract values, or pricing are public. Growth is being driven by grant-funded research collaborations (TBI-REPORTER, COVID-19 long COVID consortium), diagnostic validation paper submissions, and senior hires in product, engineering, and machine learning — indicating a transition from pure research toward a licensable clinical and pharma-facing platform rather than a scaled commercial product today.

Centile Bioscience firmographics

Firmographics
Name
Centile Bioscience
Legal name
Centile Bio
Website
https://centilebio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Centile Bioscience is a private health technology company founded in 2023 that builds AI-driven quantitative brain imaging and reference models for research institutions, academic medical centers, and pharmaceutical companies developing neurological therapeutics and clinical trial endpoints.
Ownership category
akta.pro rank

Centile Bioscience industry classification

Industry
Product category
Neuroimaging Analytics Software
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Quantitative brain imaging
  • Computational neuroscience
  • Neuroimaging analytics
  • Brain reference models
  • Neurological diagnostics

Where Centile Bioscience is headquartered

Location

Headquarters

HQ city
Bethesda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Centile Bioscience business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Research and Clinical Technology Licensing: The company appears to generate revenue through licensing its quantitative brain imaging technology and reference frameworks to research institutions, pharmaceutical companies, and healthcare organizations for use in clinical trials, drug discovery, and neurological disease research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Centile Bioscience product offering

Product offering

Core offering

Centile Bio builds advanced computational and imaging frameworks that transform complex brain data (MRI, CT) into measurable quantitative insight. Its software offerings include Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure, and an Advanced Statistical Modeling Platform for neuroimaging datasets, sold via licensing to research institutions, academic medical centers, and pharmaceutical companies for use in clinical trials, drug discovery, and neurological disease research.

Product overview

Centile Bio offers a unified quantitative neuroscience platform comprising four integrated core products: Quantitative Brain Reference Models for population-scale brain structure measurement, a Large-Scale Neuroimaging Analysis Platform for interpreting complex imaging data, Computational Modeling Infrastructure for reproducible brain analysis, and an Advanced Statistical Modeling Platform for neuroimaging datasets. These products work together to transform complex brain imaging data into measurable quantitative insight, enabling earlier detection, deeper understanding, and accelerated therapeutic discovery in neurological disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • Quantitative Brain Reference Models Population-scale statistical frameworks for measuring brain structure and variation across individuals, ages, and populations, enabling researchers to move beyond visual interpretation toward measurable, quantitative insight for neuroscience research and clinical studies.
  • Large-Scale Neuroimaging Analysis Platform Advanced statistical systems for interpreting complex brain imaging data and integrating diverse neuroimaging datasets across large cohorts, enabling consistent analysis and pattern identification for research institutions and pharmaceutical partners.
  • Computational Modeling Infrastructure
  • Advanced Statistical Modeling Platform for Neuroimaging Statistical modeling platform for neuroimaging datasets launched in 2024, supporting earlier detection of neurological changes and improved analytical tools for studying neurological disorders across research and clinical workflows.

Quantifiable outcome

  • Earlier detection of neurological disease through quantitative biological signal identification
  • +1 more outcomes

Companies that use Centile Bioscience

Customer profile

Segments2 records

Ideal customer profiles2 records

Centile Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Centile Bioscience partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • COVID-19 Consortium for Brain Charting in Long COVID PatientscoreStrategic or Co-development Partner · 1 March 2024CentileBio formed research collaboration with COVID-19 consortium to advance brain charting research specifically focused on long COVID patients, contributing to understanding of neurological impacts of the pandemic.
  • Leading Research Institutions (Global)coreStrategic or Co-development PartnerGlobal scientific collaboration with leading research institutions, clinical partners, and data initiatives advancing quantitative neuroscience discovery. Millions of brain imaging data points analyzed through these partnerships.
  • NIH/FASEBflagshipStrategic or Co-development PartnerCentile Bio team received DataWorks! Challenge grand prize from National Institutes of Health and Federation of American Societies for Experimental Biology, recognizing contributions to quantitative neuroscience research.
  • Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerMultiple team members are affiliated with CHOP including CEO Jakob Seidlitz and Scientific Advisor Aaron Alexander-Bloch. The company leverages CHOP's research infrastructure and neuroimaging capabilities.
  • Scandx AB SwedencoreStrategic or Co-development PartnerMichael and Meera joined as co-founders through exclusive deal with Scandx AB Sweden, bringing additional expertise and technology to Centile Bio.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Centile Bioscience competitors and assessment

Company assessment

Direct peers

  • Brainreader: Brainreader offers AI-based brain MRI volumetrics (Neuroreader) used by clinicians and pharma trials to quantify brain changes — comparable product and customer overlap with Centile's quantitative measurement products.
  • icometrix: icometrix develops AI software (icobrain) that quantitatively analyzes brain MRI/CT scans for neurological conditions including MS, dementia and TBI — the closest direct peer to Centile's quantitative brain reference and imaging-analysis platform.
  • QMENTA: QMENTA provides a cloud-based neuroimaging analysis platform for clinical trials and research, very analogous to Centile's large-scale neuroimaging analysis infrastructure for multi-site brain studies.
  • CorTechs Labs (NeuroQuant): CorTechs Labs commercializes NeuroQuant, an FDA-cleared brain MRI volumetric analysis tool widely used in clinical practice; directly comparable to Centile's quantitative brain measurement and diagnostic validation roadmap.
  • Octave Bioscience: Octave Bioscience builds AI-enabled multi-modal diagnostics for neurodegenerative diseases (notably MS); Centile's CSPO Kelly Leyden previously led product there, and the company competes for the same neurology-diagnostics B2B customer base.

Broad incumbents

  • Siemens Healthineers: Siemens Healthineers is a major MRI and imaging AI incumbent whose AI-Rad Companion and neurology analytics compete or partner with vendors like Centile in quantitative brain measurement.
  • Aidoc: Aidoc is a broad AI-imaging vendor with FDA-cleared algorithms deployed across hospital radiology workflows; competes for enterprise imaging-AI budgets that Centile would also target via its neurology-focused platform.
  • GE Healthcare: GE Healthcare is a large incumbent in MRI equipment and increasingly AI-augmented neuroimaging analytics; represents the platform/channel partner versus which Centile's AI must differentiate.

Emerging players

  • Neotiv: Neotiv develops digital biomarkers and AI analysis for memory and early Alzheimer's detection, overlapping with Centile's AD validation work in the same neurodegenerative diagnostic category.
  • Altoida: Altoida builds AI-based digital cognitive and brain-health assessment tools targeting early detection of neurodegenerative disease, addressing similar end-markets via a different (digital-cognitive) modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Centile Bioscience social profiles

Digital presence

Centile Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Centile Bioscience leadership team

Management profile

Number of profiles

Profiles7 records

Centile Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Centile Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centile Bioscience

What does Centile Bioscience do?

Centile Bio builds advanced computational and imaging frameworks that transform complex brain data (MRI, CT) into measurable quantitative insight. Its software offerings include Quantitative Brain Reference Models, a Large-Scale Neuroimaging Analysis Platform, Computational Modeling Infrastructure, and an Advanced Statistical Modeling Platform for neuroimaging datasets, sold via licensing to research institutions, academic medical centers, and pharmaceutical companies for use in clinical trials, drug discovery, and neurological disease research.

Is Centile Bioscience a public or private company?

Centile Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Centile Bioscience founded?

Centile Bioscience was founded in 2023. It employs 1 to 10 people.

Where is Centile Bioscience based?

Centile Bioscience is headquartered in Bethesda, United States, in the North America region.

How does Centile Bioscience make money?

One revenue line is on record: research and Clinical Technology Licensing.

Who are Centile Bioscience's main competitors?

Direct peers on record are Brainreader, icometrix, QMENTA, CorTechs Labs (NeuroQuant) and Octave Bioscience. Broad incumbents are Siemens Healthineers, Aidoc and GE Healthcare. Emerging players are Neotiv and Altoida.

Does Centile Bioscience have an API?

No public API is recorded for Centile Bioscience.

What industry is Centile Bioscience in?

Centile Bioscience's product category is Neuroimaging Analytics Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 54171 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales